tiprankstipranks
Trending News
More News >

Bicycle Therapeutics price target lowered to $14 from $17 at B. Riley

B. Riley lowered the firm’s price target on Bicycle Therapeutics (BCYC) to $14 from $17 and keeps a Neutral rating on the shares following the Q1 report. The firm says the company faces significant competition from Padcev -plus pembro in bladder cancer, and a shift toward novel pipeline programs appears unlikely based on current activity.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1